Using targeted radiation therapy for prostate cancer that resists standard treatment
Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy
This study is testing a new type of targeted radiation therapy for men with prostate cancer that isn't responding to standard treatment, to see if it can help control their cancer while they continue their current medication.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT04838899 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of stereotactic ablative body radiotherapy (SABR) to treat oligoprogressive metastatic prostate cancer in patients who are already receiving abiraterone therapy. The approach aims to locally ablate progressing metastatic tumors while allowing the patient to continue their current systemic therapy, potentially delaying the need for more aggressive treatments. By focusing on a limited number of progressing lesions, the study seeks to improve progression-free survival and overall patient outcomes. The trial will evaluate the effectiveness of this method in a population with limited treatment options.
Who should consider this trial
Good fit: Ideal candidates are men with metastatic castration-resistant prostate cancer who are currently on abiraterone and have evidence of oligoprogression.
Not a fit: Patients with widespread clinical progression or those requiring immediate aggressive treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could help patients maintain their current treatment longer and improve their quality of life.
How similar studies have performed: While there is limited evidence for this specific approach in prostate cancer, similar strategies have shown promise in other cancer types like renal cell and non-small cell lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ECOG performance status 0-1. * Histologic confirmation of prostate adenocarcinoma. * Documentation of metastatic, castration-resistant prostate cancer. * Patient being treated with abiraterone. * Evidence of oligoprogression (according to RECIST \[V1.1\] and/or Prostate Cancer Working Group criteria \[PCWG3\], as applicable), applying any of the following: (i) ≤ 5 metastatic lesions progressing on conventional imaging (≤ 3 progressing metastases in any one organ system) while all other metastases are controlled or responding; (ii) PSA progression only, but in the setting of oligometastases (≤ 5 metastatic lesions seen on imaging, with ≤ 3 metastases in any one organ system); in this setting, all metastases will be irradiated. * All metastases of interest amenable to SABR. Exclusion Criteria: * Patients presenting with unequivocal clinical progression, defined as one of the following: (i) cancer pain requiring the initiation of opioid therapy; (ii) immediate need for cytotoxic chemotherapy as per treating physician's discretion; or (iii) deterioration of performance status to grade ≥ 3 according to ECOG. * Evidence of spinal cord compression. * Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, and in-situ cancer.
Where this trial is running
Toronto, Ontario
- Odette Cancer Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Urban Emmenegger, MD
- Email: urban.emmenegger@sunnybrook.ca
- Phone: +416-480-4928
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.